Cargando…
FKBP5 blockade may provide a new horizon for the treatment of stress‐associated disorders: An in‐silico study
OBJECTIVE: We searched for, from the FDA (Food and Drug Administration‐USA)‐approved drugs, inhibitors of FKBP5 with tolerable adverse effect profiles (eg, mild headache, sedation, etc.) and with the ability to cross the blood brain barrier (BBB), using bio‐informatics tools (in‐silico). This may pa...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235572/ https://www.ncbi.nlm.nih.gov/pubmed/37078238 http://dx.doi.org/10.1002/epi4.12749 |